Comparison of Cefiderocol Plus Ampicillin-sulbactam Versus Colistin With or Without Meropenem for Treating Carbapenem-Resistant Acinetobacter Baumannii Bloodstream and Lung Infections
Led by Rambam Health Care Campus · Updated on 2025-08-01
734
Participants Needed
3
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatment options for patients with bloodstream infections, hospital-acquired pneumonia, or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii CRAB. The study compares a combination of cefiderocol and ampicillin-sulbactam to treatments involving colistin alone or colistin combined with meropenem. This prospective controlled clinical study uses historical controls from previous randomized trials to assess these treatments in real-world hospital settings in Israel and Italy.
The study involves two treatment groups one receiving cefiderocol 2 grams intravenously every 8 hours plus ampicillin-sulbactam 3 grams intravenously every 6 hours, both given as extended infusions over 3 hours. Dosages are adjusted based on kidney function and renal replacement therapies. The comparison group consists of patients treated with a colistin loading dose of 9 million units intravenously followed by 4.5 million units, with or without meropenem 2 grams intravenously as an extended infusion. The study plans to recruit 150 patients and compare outcomes with historical data from earlier trials.
Participants will be monitored for outcomes including all-cause mortality at 28 days, clinical and microbiological failure, resistance development, hospital stay length, functional capacity decline, and adverse events such as Clostridiodes difficile infection, kidney failure, and liver injury. Assessments occur at multiple time points up to 28 days. The study follows patients closely during treatment and tracks safety and effectiveness measures to better understand treatment impacts for these serious infections.
CONDITIONS
Brief Title
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
Research Team
M
Mical Paul
M
Marco Falcone
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of bloodstream infection or hospital-acquired pneumonia/ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii
Bacteria must be resistant to meropenem and/or imipenem (MIC >8 5g/mL)
Bacteria must be susceptible to cefiderocol (disc zone diameter 17 mm, MIC <2 5g/mL)
Infection attributed to CRAB if CRAB isolated from respiratory sample within 7 days before pneumonia diagnosis
You will not qualify if you...
More than 72 hours of antibiotic therapy effective against CRAB within 96 hours before enrollment
Infection with carbapenem-susceptible pathogens deemed clinically significant
Carbapenem-resistant Acinetobacter baumannii susceptible to any beta-lactam other than cefiderocol
COVID-19 co-infection
Immediate allergy to penicillin
Pregnant women
Previous participation in this trial
Lack of informed consent
Infection requiring treatment over 14 days
Life expectancy less than 24 hours or antibiotic treatment considered futile
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 14 days
Participants receive either cefiderocol combined with ampicillin-sulbactam or colistin with or without meropenem to treat carbapenem-resistant Acinetobacter baumannii infections.
Daily visits while receiving treatment
Follow-up
Duration - 28 days
Participants are monitored for outcomes including all-cause mortality, clinical and microbiological failure, resistance development, and adverse events for 28 days after treatment.
Regular follow-up visits during 28 days post-treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Comparison of Cefiderocol Plus Ampicillin-sulbactam Versus Colistin With or Without Meropenem for Treating Carbapenem-Resistant Acinetobacter Baumannii Bloodstream and Lung Infections
TREAT-GNB Phase 4 Trial Evaluating Antibiotic Treatments for Severe Carbapenem-Resistant Gram-Negative Bacterial Infections in Bloodstream and Lung
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Mical Paul, George L Daikos, Emanuele Durante-Mangoni...